- NAACP: Detroit water shutoffs are racially motivated
- Obama family set to buy $4.25M desert home in California: report
- Big milestone for Britain’s little Prince George who turns 1
- Murphy: Israel must be wary of Hamas using civilian deaths for recruitment
- Royce: Putin recruiting ‘every skinhead and malcontent around Russia’
- Nancy Pelosi is adamant: Congress worked together when Bush was president
- ‘Slender Man’ stabbing victim receives Purple Heart from anonymous veteran
- Kentucky city called socialist for buying gas station, undercutting competitor fuel prices
- Israel hits five mosques, sports complex in overnight Gaza strikes
- Hillary Clinton dogged for refusing reporters’ questions on book tour
Feds: Novartis to pay more than $400M in penalties
Question of the Day
PHILADELPHIA (AP) - Novartis Pharmaceuticals Corp. will plead guilty to charges it marketed an epilepsy medicine for unapproved uses and pay $422.5 million in civil and criminal penalties, federal officials announced Thursday.
The company agreed to pay a criminal fine and forfeiture totaling $185 million for the off-label promotion of Trileptal, U.S. Attorney Zane Memeger said at news conference in Philadelphia.
Novartis will also pay $237.5 million to resolve civil liabilities over off-label marketing of Trileptal and for paying kickbacks to health care providers in an effort to get them to prescribe that and five other drugs.
“Every day in this country, patients rely on sound advice from their doctors,” Memeger said. “Off-label marketing … can undermine the doctor-patient relationship.”
While doctors are permitted to prescribe medications for unapproved uses based on their medical experience, pharmaceutical companies are not allowed to market or promote drugs for uses not approved by the Food and Drug Administration, Memeger said.
“That legal obligation takes priority over generating profits,” he said.
Federal prosecutors do not allege any patients were harmed by the off-label marketing.
The announcement Thursday also resolves four whistle-blower lawsuits filed by former Novartis employees who reported the off-label marketing. They will share $25.6 million of the penalty money.
Novartis Pharmaceuticals, based in East Hanover, N.J., is a subsidiary of Swiss company Novartis AG, the world’s third-biggest drug maker by revenue.
A spokeswoman did not immediately return a call seeking comment.
TWT Video Picks
U.S. appetite for drugs begets violence migrants are fleeing
- IRS seeks help destroying another 3,200 computer hard drives
- Rep. Jared Polis' anti-fracking crusade riles Colorado
- Obamacare dealt massive setback by federal appeals court
- Jewish woman booted from JetBlue flight over fight with Palestinian
- LYONS: Small-arms treaty, big Second Amendment threat
- MERRY: Handicaps in Hillary's way
- PRUDEN: A deadly enemy within exacerbating immigration crisis
- YOUNG: A sinking presidency, deeper after November?
- Hamas terrorists wear Israeli army uniforms to ambush soldiers in Gaza
- Hillary Clinton dogged for refusing reporters' questions on book tour
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world
Fighting in Iraq